Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

VectivBio Holding AG Create: Alert

All | News | Filings
Date FiledTypeDescription
07/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Articles of Association of VectivBio Holding AG, as amended",
"Articles of Association of VectivBio Holding AG, as amended"
06/29/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares BOSTON and BASEL, Switzerland - June 29, 2023 - Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, and VectivBio Holding AG , a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio for $17.00 per share in cash . The Depositary for the Tender Offer has advised Ironwood and VectivBio that at the end of the offering period, 59,287,753 Shares had been tendered and not withdrawn pursuant to the Tender Offer and it has received commitments to tender 2,007,310 additional Shares under the guaran..."
06/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio BOSTON and BASEL, Switzerland - June 16, 2023 - Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, and VectivBio Holding AG , a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended , in connection with Ironwood's pending acquisition of VectivBio, expired at 11:59 p.m., Eastern Time, on June 15, 2023. As previously announced on May 22, 2023, Ironwood commenced a tender offer to purchase all of VectivBio's outstanding ordinary shares for $17.00 per share in cash. T..."
06/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Invitation to the Extraordinary General Meeting of Shareholders",
"Invitation to the Extraordinary General Meeting of Shareholders"
06/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Articles of Association, as amended"
05/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Invitation to the 2023 Annual General Meeting",
"Twitter"
04/19/2023 6-K Quarterly results
04/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Announcement of the Date of the Annual General Meeting of Shareholders",
"Announcement of the Date of the Annual General Meeting of Shareholders"
01/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
12/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
12/09/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"VectivBio Announces Results of Extraordinary General Meeting December 9, 2022 Wouter Joustra Elected to the Board of Directors BASEL, Switzerland, Dec. 9, 2022 — VectivBio Holding AG , a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022. Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio. He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner. At Forbion, Mr. Joustra is responsible for deal origination, general portfolio m..."
11/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Invitation to the Extraordinary General Meeting of Shareholders",
"VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders BASEL, Switzerland, November 16, 2022 — VectivBio Holding AG , a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the Extraordinary General Meeting, which will be held on Friday, December 9, 2022, at 10:00 a.m. CET / 4:00 a.m. EST at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland. The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors. In view of the ongoing COVID-19 pandemic, and in accordance with the Ordinance 3 of the Swiss Federal Council regarding measures on combatting the coronavirus ..."
10/18/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Underwriting Agreement, by and among the Company and Jefferies LLC, SVB Securities LLC and Piper Sandler & Co",
"Articles of Association of the registrant, as amended",
"Opinion of Homburger AG",
"VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares BASEL, Switzerland, Oct. 13, 2022 - VectivBio Holding AG , a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of an underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share. Investors who have agreed to purchase shares in the offering include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion's Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital , TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors. Before deducting the underwriting discounts and...",
"VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares BASEL, Switzerland, October 18, 2022 - VectivBio Holding AG , a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share. Investors who purchased shares in the offering include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion's Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital , TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors. Before deducting the underwriting di..."
10/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
10/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients with Colon-In-Continuity",
"Presentation of the Company dated October 2022",
"VectivBio Publishes Invitation to the Extraordinary General Meeting BASEL, Switzerland, October 12, 2022 — VectivBio Holding AG , a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Meeting, which will be held on Friday, December 9, 2022, at 10:00 a.m. CEST / 4:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland. The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors. In view of the ongoing COVID-19 pandemic, and in accordance with the Ordinance 3 of the Swiss Federal Council regarding measures on combatting the coronavirus , the Extraordinary Ge...",
"Announcement of the Extraordinary General Meeting of Shareholders",
"Unaudited Condensed Consolidated Interim Financial Statements",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations"
07/01/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Articles of Association, as amended"
06/16/2022 6-K Quarterly results
06/09/2022 6-K Quarterly results
04/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"VectivBio Reports Full Year 2021 Financial Results and Provides Business Update Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022",
"2021 IFRS Consolidated Financial Statements",
"2021 Statutory Annual Report",
"2021 Compensation Report",
"VectivBio Holding AG Corporate Presentation"
03/30/2022 6-K Quarterly results
10/29/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Interim Condensed Consolidated Statement of Financial Position for the Six Months Ended June 30, 2021",
"Unaudited Interim Condensed Consolidated Statement of Income (Loss) for the Six Months Ended June 30, 2021"
09/03/2021 6-K Quarterly results
08/31/2021 6-K Quarterly results
08/12/2021 6-K Quarterly results
07/12/2021 6-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy